Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses

Jung Yeon Moon; Kyung Eun Lee; Byung Chul Chang; Eurim Jeong; Hotcherl Jeong; Hye Sun Gwak

doi:10.1097/FPC.0000000000000103

Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses

Jung Yeon Moon, Kyung Eun Lee, Byung Chul Chang, Eurim Jeong, Hotcherl Jeong, Hye Sun Gwak

Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

A possible association between the combination of genetic variations in hepatocyte nuclear factor 4α (HNF4α) and constitutive androstane receptor (CAR) and the stable doses of warfarin was examined in patients from the Ewha-Severance Treatment (EAST) Group of Warfarin. Around 42.5% of the overall interindividual variability in warfarin dose requirements was explained by the multivariate regression model; the vitamin K epoxide reductase complex 1 (VKORC1) genotype accounted for 29.6%, the cytochrome P450 (CYP) 2C9 genotype for 4.3%, age for 3.6%, the CYP4F2 genotype for 3.3%, and CAR/HNF4α (rs2501873/rs3212198) for 1.7%. Our results showed that the combination of CAR and HNF4α genotypes could be determinants of stable warfarin doses.

Original language	English
Pages (from-to)	38-40
Number of pages	3
Journal	Pharmacogenetics and Genomics
Volume	25
Issue number	1
DOIs	https://doi.org/10.1097/FPC.0000000000000103
State	Published - 14 Jan 2015

Keywords

CYP2C9
Constitutive androstane receptor
Hepatocyte nuclear factor 4α
Transcription factor
Warfarin

Access to Document

10.1097/FPC.0000000000000103

Cite this

@article{9e07b75954914a209e8daa754918a429,

title = "Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses",

abstract = "A possible association between the combination of genetic variations in hepatocyte nuclear factor 4α (HNF4α) and constitutive androstane receptor (CAR) and the stable doses of warfarin was examined in patients from the Ewha-Severance Treatment (EAST) Group of Warfarin. Around 42.5% of the overall interindividual variability in warfarin dose requirements was explained by the multivariate regression model; the vitamin K epoxide reductase complex 1 (VKORC1) genotype accounted for 29.6%, the cytochrome P450 (CYP) 2C9 genotype for 4.3%, age for 3.6%, the CYP4F2 genotype for 3.3%, and CAR/HNF4α (rs2501873/rs3212198) for 1.7%. Our results showed that the combination of CAR and HNF4α genotypes could be determinants of stable warfarin doses.",

keywords = "CYP2C9, Constitutive androstane receptor, Hepatocyte nuclear factor 4α, Transcription factor, Warfarin",

author = "Moon, {Jung Yeon} and Lee, {Kyung Eun} and Chang, {Byung Chul} and Eurim Jeong and Hotcherl Jeong and Gwak, {Hye Sun}",

note = "Publisher Copyright: {\textcopyright} 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.",

year = "2015",

month = jan,

day = "14",

doi = "10.1097/FPC.0000000000000103",

language = "English",

volume = "25",

pages = "38--40",

journal = "Pharmacogenetics and Genomics",

issn = "1744-6872",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "1",

}

TY - JOUR

T1 - Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses

AU - Moon, Jung Yeon

AU - Lee, Kyung Eun

AU - Chang, Byung Chul

AU - Jeong, Eurim

AU - Jeong, Hotcherl

AU - Gwak, Hye Sun

PY - 2015/1/14

Y1 - 2015/1/14

N2 - A possible association between the combination of genetic variations in hepatocyte nuclear factor 4α (HNF4α) and constitutive androstane receptor (CAR) and the stable doses of warfarin was examined in patients from the Ewha-Severance Treatment (EAST) Group of Warfarin. Around 42.5% of the overall interindividual variability in warfarin dose requirements was explained by the multivariate regression model; the vitamin K epoxide reductase complex 1 (VKORC1) genotype accounted for 29.6%, the cytochrome P450 (CYP) 2C9 genotype for 4.3%, age for 3.6%, the CYP4F2 genotype for 3.3%, and CAR/HNF4α (rs2501873/rs3212198) for 1.7%. Our results showed that the combination of CAR and HNF4α genotypes could be determinants of stable warfarin doses.

AB - A possible association between the combination of genetic variations in hepatocyte nuclear factor 4α (HNF4α) and constitutive androstane receptor (CAR) and the stable doses of warfarin was examined in patients from the Ewha-Severance Treatment (EAST) Group of Warfarin. Around 42.5% of the overall interindividual variability in warfarin dose requirements was explained by the multivariate regression model; the vitamin K epoxide reductase complex 1 (VKORC1) genotype accounted for 29.6%, the cytochrome P450 (CYP) 2C9 genotype for 4.3%, age for 3.6%, the CYP4F2 genotype for 3.3%, and CAR/HNF4α (rs2501873/rs3212198) for 1.7%. Our results showed that the combination of CAR and HNF4α genotypes could be determinants of stable warfarin doses.

KW - CYP2C9

KW - Constitutive androstane receptor

KW - Hepatocyte nuclear factor 4α

KW - Transcription factor

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84918510873&partnerID=8YFLogxK

U2 - 10.1097/FPC.0000000000000103

DO - 10.1097/FPC.0000000000000103

M3 - Article

C2 - 25356900

AN - SCOPUS:84918510873

SN - 1744-6872

VL - 25

SP - 38

EP - 40

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

IS - 1

ER -

Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses

Abstract

Keywords

Access to Document

Fingerprint

Cite this